Linked Life Data

7572426

Source:http://linkedlifedata.com/resource/pubmed/id/7572426

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1995-11-14
pubmed:abstractText
This paper investigates some of the characteristics which a vaccine for schistosomiasis would require to be more cost-effective than chemotherapy. The impact of a variety of possible vaccination scenarios are assessed in terms of the discounted years of heavy infection prevented in children, and the cost-effectiveness of these approaches are compared with annual mass treatment. The analyses demonstrate that the three critical parameters determining whether a vaccine would ever be more cost-effective than mass chemotherapy are price, duration of protection and efficacy. If the vaccine had sufficient duration of protection to be delivered through the regular childhood immunization programmes (EPI), it could be more cost-effective than annual chemotherapy. The necessary condition is that adding the vaccine to EPI must not cost more than $4.30 per person in excess of one round of chemotherapy. For a shorter duration of vaccine protection, the schistosomiasis vaccine could not exceed the cost (including delivery costs) of one round of annual chemotherapy by more than approximately $3.50.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0001-706X
pubmed:author
pubmed:issnType
Print
pubmed:volume
59
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
197-209
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Desirable characteristics of a schistosomiasis vaccine: some implications of a cost-effectiveness analysis.
pubmed:affiliation
Department of Public Health and Epidemiology, Swiss Tropical Institute, Basel.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't